BRAF and melanoma: When CHL1 melanoma cells (wild-type BRAF) were treated with BRAF inhibitor vemurafenib, it induced the paradoxical elevation of ERK phosphorylation as expected in wild-type BRAF cells [26]–[28], but triggered no change of pAKT.